Introduction to Impella RP: The Gold Standard in Right Ventricular Support

The Impella RP (Right Percutaneous) system represents a paradigm shift in the management of acute right heart failure. As an orthopedic and cardiac support specialist, understanding the intersection of mechanical circulatory support (MCS) and hemodynamics is crucial. Unlike traditional surgical pump systems that require invasive sternotomy, the Impella RP is a percutaneous, catheter-based micro-axial flow pump designed to offload the right ventricle (RV) and restore systemic perfusion.

In patients suffering from acute right heart failure—often secondary to myocardial infarction, post-cardiotomy shock, or pulmonary embolism—the Impella RP serves as a bridge to recovery or decision-making. By actively pumping blood from the inferior vena cava (IVC) across the pulmonic valve into the pulmonary artery, the device bypasses the failing RV, reducing myocardial oxygen demand and preventing the lethal cycle of RV dilation and subsequent left ventricular (LV) failure.

Technical Specifications and Biomechanical Mechanisms

The Impella RP is a masterpiece of miniaturized engineering. It is designed to be inserted percutaneously through the femoral vein, threaded through the right atrium and right ventricle, and positioned across the pulmonic valve.

Core Design Components

• Micro-Axial Pump: The device utilizes a high-speed impeller capable of generating flow rates up to 4.0 liters per minute.
• Cannula Geometry: The distal end is designed to reside in the pulmonary artery, while the inflow cage sits in the IVC/Right Atrium junction.
• Purge System: A continuous dextrose-based purge solution is used to maintain pump pressure and prevent blood ingress into the motor, ensuring long-term durability.
• Controller Interface: The Automated Impella Controller (AIC) provides real-time monitoring of motor current, flow, and pump position.

Biomechanical Principles

The device operates on the principle of continuous axial flow. By creating a pressure gradient that facilitates blood flow from the IVC to the pulmonary artery, the Impella RP effectively "unloads" the right ventricle. This reduction in RV end-diastolic pressure (RVEDP) decreases wall stress, allowing for myocardial recovery and improved coronary perfusion pressure.

Clinical Indications and Surgical Application

The Impella RP is indicated for the treatment of acute right heart failure or decompensation following left ventricular assist device (LVAD) implantation, myocardial infarction, heart transplant, or open-heart surgery.

Surgical Insertion Protocol

1. Access: Ultrasound-guided access is obtained via the common femoral vein.
2. Guidewire Placement: A 0.027" guidewire is advanced through the right atrium, across the right ventricle, and into the pulmonary artery under fluoroscopic guidance.
3. Deployment: The Impella RP is tracked over the wire. The inflow cage must be positioned in the right atrium/IVC, while the outflow is situated in the main pulmonary artery.
4. Verification: Precise placement is verified via echocardiography (TTE or TEE) and pressure waveforms.

Clinical Usage Considerations

• Anticoagulation: Patients must be maintained on systemic heparinization to prevent device-related thrombosis, with target ACT levels typically between 160–180 seconds.
• Hemodynamic Monitoring: Continuous monitoring of the Pulmonary Artery Pressure (PAP) and Central Venous Pressure (CVP) is mandatory to assess the efficacy of the unloading.

Risks, Contraindications, and Safety Protocols

While the Impella RP is life-saving, it carries inherent risks that require a multidisciplinary clinical approach.

Primary Contraindications

• Anatomical: Severe tricuspid or pulmonary valve stenosis/regurgitation.
• Vascular: Significant peripheral artery/vein disease that precludes large-bore access.
• Cardiac: Presence of a mechanical tricuspid valve or severe pulmonary artery calcification.
• Coagulopathy: Uncontrolled bleeding disorders that prevent the use of anticoagulants.

Potential Side Effects

• Vascular Complications: Bleeding at the access site, pseudoaneurysm, or limb ischemia.
• Hemolysis: Excessive motor speed or poor positioning can result in red blood cell destruction.
• Thrombosis: Risk of pump thrombosis if anticoagulation is subtherapeutic.
• Infection: Catheter-related bloodstream infections.

Maintenance and Sterilization Protocols

The Impella RP is a single-use, sterile device. It cannot be re-sterilized or reused. Strict adherence to aseptic technique during insertion is paramount to prevent endocarditis.

• Purge Maintenance: The purge system must be checked every 2–4 hours. A sudden increase in purge pressure may indicate a blockage or kink in the line.
• System Integrity: The AIC (Automated Impella Controller) should be kept plugged into AC power whenever possible.
• Site Care: The femoral access site requires daily assessment for hematoma, signs of infection, or limb ischemia.

Patient Outcome Improvements

Clinical trials, including the RECOVER RIGHT study, have demonstrated significant improvements in hemodynamic parameters for patients supported by the Impella RP.

• Cardiac Index (CI): Patients typically see an immediate rise in CI, often increasing from <1.8 L/min/m² to >2.5 L/min/m².
• Reduction in CVP: A consistent decrease in Central Venous Pressure is observed, which alleviates venous congestion in the liver and kidneys, promoting organ recovery.
• Survival Rates: The device has shown a significant survival advantage in patients who would otherwise have faced near-certain mortality due to refractory right-sided heart failure.

Frequently Asked Questions (FAQ)

1. What is the maximum duration the Impella RP can be used?

The Impella RP is FDA-approved for short-term support, typically up to 14 days. Extended support requires a formal clinical review and risk assessment.

2. Can the Impella RP be used in patients with an existing LVAD?

Yes, it is specifically indicated for patients who develop right heart failure after the implantation of a Left Ventricular Assist Device (BIVAD support).

3. How is the Impella RP different from the Impella 5.5?

The Impella RP is designed for the right side of the heart (IVC to Pulmonary Artery), whereas the Impella 5.5 is designed for the left side (LV to Aorta).

4. What should I do if the pump flow drops suddenly?

Check the purge pressure and verify the pump position via echocardiogram. A drop in flow often suggests migration of the pump or an obstruction in the inflow cage.

5. Is heparin mandatory while the device is in place?

Yes, systemic anticoagulation is essential to prevent thrombus formation on the impeller blades and the catheter body.

6. Can the patient be mobilized while on Impella RP?

Generally, patients on Impella RP are kept on bed rest to prevent device migration and vascular access complications.

7. How does the device affect tricuspid valve function?

The device passes through the tricuspid valve. While it does not typically cause severe regurgitation, clinicians should monitor for worsening tricuspid valve performance.

8. What is the role of the purge solution?

The purge solution creates a positive pressure barrier that prevents blood from entering the motor, which would lead to motor failure and thrombosis.

9. What is the most common complication during insertion?

The most common complications are access-site bleeding and vascular injury to the femoral vein.

10. How is the device removed?

Removal is performed in a controlled setting, usually in the ICU or cath lab, with careful attention to achieving hemostasis at the femoral access site, often using a pre-placed closure device.

Conclusion

The Impella RP is an essential tool in the modern cardiac intensive care unit. By providing rapid, efficient, and reliable right ventricular support, it allows the heart time to recover from acute insults. Success with the Impella RP relies on meticulous surgical technique, vigilant monitoring of the AIC, and a robust anticoagulation strategy. As technology advances, we expect these devices to become even more streamlined, further improving the survival rates and quality of life for patients facing the direst of cardiac conditions.